...
首页> 外文期刊>The American Journal of Clinical Nutrition: Official Journal of the American Society for Clinical Nutrition >Bioavailability of polyglutamyl folic acid relative to that of monoglutamyl folic acid in subjects with different genotypes of the glutamate carboxypeptidase II gene.
【24h】

Bioavailability of polyglutamyl folic acid relative to that of monoglutamyl folic acid in subjects with different genotypes of the glutamate carboxypeptidase II gene.

机译:在具有不同基因型谷氨酸羧肽酶II基因的受试者中,聚谷氨酰叶酸相对于单谷氨酰叶酸的生物利用度。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Before dietary folate is absorbed, polyglutamate folates are deconjugated to monoglutamates by folylpoly-gamma-glutamyl carboxypeptidase in the small intestine. The 1561T allele of the glutamate carboxypeptidase II gene (GCPII), which codes for folylpoly-gamma-glutamyl carboxypeptidase, may impair intestinal absorption of dietary folates. OBJECTIVE: Our aim was to study the bioavailability of polyglutamyl folic acid relative to that of monoglutamyl folic acid across GCPII 1561 genotypes. DESIGN: In a randomized study, 180 healthy adults aged 50-75 y received 323 nmol monoglutamyl folic acid/d (n = 59), 262 nmol heptaglutamyl folic acid/d (n = 61), or placebo (n = 60) for 12 wk. Genotypes were assessed after the intervention. The bioavailability of heptaglutamyl folic acid relative to that of monoglutamyl folic acid was calculated by using the changes in serum folate concentration in the treatment groups, after correction for changes in the placebo group and for the administered dose. RESULTS: No subjects with the TT genotype were encountered. At baseline, serum and erythrocyte folate concentrations were higher (P < 0.05) in subjects with the CT genotype [16.3 nmol/L (geometric x; 95% CI: 13.7, 19.3 nmol/L) and 863 nmol/L (735, 1012 nmol/L), respectively; n = 19] than in subjects with the CC genotype [13.7 (13.1, 14.3) and 685 (652, 721) nmol/L, respectively; n = 161]. Baseline homocysteine concentrations were not significantly different between genotypes. The bioavailability of heptaglutamyl folic acid relative to that of monoglutamyl folic acid was not significantly different between subjects with the CC (64%; 52%, 76%) and CT genotypes (70%; 49%, 91%). CONCLUSIONS: The 1561T allele of the GCPII gene does not impair the bioavailability of polyglutamyl folic acid. However, the allele is associated with higher folate status. This association may be explained by yet unidentified factors controlling the expression of the GCPII gene.
机译:背景:在饮食中吸收叶酸之前,聚谷氨酸叶酸通过小肠中的叶酰聚-γ-谷氨酰基羧肽酶与单谷氨酸解偶联。谷氨酸羧肽酶II基因(GCPII)的1561T等位基因可能编码膳食叶酸对肠道的吸收,该基因编码叶酰聚-γ-谷氨酰羧肽酶。目的:我们研究了GCPII 1561基因型中聚谷氨酰叶酸相对于单谷氨酰叶酸的生物利用度。设计:在一项随机研究中,180名年龄在50-75岁的健康成年人接受了323 nmol单谷氨酰叶酸/ d(n = 59),262 nmol七谷氨酰叶酸/ d(n = 61)或安慰剂(n = 60)的治疗12周。干预后评估基因型。在校正了安慰剂组和给药剂量的变化之后,通过使用治疗组中血清叶酸浓度的变化来计算七谷氨酰叶酸相对于单谷氨酰叶酸的生物利用度。结果:没有遇到TT基因型的受试者。在基线时,CT基因型[16.3 nmol / L(几何x; 95%CI:13.7、19.3 nmol / L)和863 nmol / L(735、1012)的受试者的血清和红细胞叶酸浓度较高(P <0.05) nmol / L); n = 19],而CC基因型分别为[13.7(13.1,14.3)和685(652,721)nmol / L。 n = 161]。基线高半胱氨酸浓度在基因型之间没有显着差异。在CC(64%; 52%,76%)和CT基因型(70%; 49%,91%)的受试者之间,七谷氨酸叶酸的生物利用度相对于单谷氨酰叶酸的生物利用度没有显着差异。结论:GCPII基因的1561T等位基因不会损害聚谷氨酰叶酸的生物利用度。然而,等位基因与较高的叶酸状态相关。可以通过控制GCPII基因表达的尚未确定的因素来解释这种关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号